PTO/SB/05 (06-03)

UTILITY
PATENT APPLICATION
TRANSMITTAL

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Attorney Docket No. 014058-010620US

First Inventor Johnson, David A.

TIUS NOVEL AMPHIPATHIC ALDEHYDES AND THEIR

USE AS ADJUVANTS AND IMMUNOEFFECTORS

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Express Mail Label No. EV 330854845 US

APPLICATION ELEMENTS					ADDE	ADDRESS TO Mail Stop Patent Application Commissioner for Patents				
See MPEP chapter 600 concerning design patent application contents.					ADDIN	P.O. Box 1450 Alexandria, VA 22313-1450				
	Fee Transmittal				7. CD-ROM or CD-R in duplicate, large table or					
	(Submit an original and a duplicate for fee processing)					Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission				
	Applicant claims small entity status. See 37 CFR 1.27.					8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)				
	Specification [Total Pages 72]					a. Computer Readable Form (CRF)				
	preferred arrange				b. Specification Sequence Listing on:					
	Descriptive title o Cross Reference			 i. ☐ CD-ROM or CD-R (2 copies); or ii. ☐ paper number of pages 						
	- Statement Regarding Fed sponsored R & D					c. Statements verifying identity of above copies				
Reference to sequence listing, a table, or a computer program listing appendix Background of the Invention Brief Summary of the Invention Brief Description of the Drawning if filed)					T-4-5	ACCOMPANYING APPLICATIONS PARTS				
						9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of (when there is an essignee) Attorney				
	- Detailed Description									
	- Claim(s) - Abstract of the Disclosure									
_	_									
	Drawing(s) (35 U.S.C.113) [Total Sheets]					12. Information Disclosure Copies of IDS				
5. Oath or Declaration [Total Pages 2]					13. ⊠	Statement (IDS)/PTO-1449 Citations 13. Preliminary Amendment				
Newly executed (original or copy)					14. 🖾					
0. 23 Copy Ilom a prior application (57 CFK 1.65 (d))							Should be specifically itemized)			
(for a continuation/divisional with Box 18 completed)					15.	15. Certified Copy of Priority Document(s)				
i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s)					1 _	(if foreign priority is claimed)				
named in the prior application, see 37 CFR					16.	 Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 				
1.63(d)(2) and 1.33(b).					1	or its equivalent				
6. Application Data Sheet. See 37 CFR 1.76										
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of										
the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:										
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 09/810.915										
Prior application information: Examiner Ceperley, Mary Art Unit: 1641 For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is										
For CONTINGATION of DIVISIONAL AFFS only. The entire disabsure of the pixel application, nor which an outling declaration is supplied under Box 5b. is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby										
incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the										
submitted application parts.										
19. CORRESPONDENCE ADDRESS										
⊠ Customer Number 20350										
⊠ Customer Number				20.	20350			OR Correspondence address below		
Name	l									
Address										
City	ļ									
				State	ļ	Zi				
Country			Telepi	none	<u> </u>		Fax			
Name (Print/Type) Jorel G. Act			erman		Registration	Registration No. (Attorney/Agent)			24,307	
Signature						Date			August 27 , 2003	

PTO/SB/17 (05-03) Approved for use through 04/30/2003, OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of inform ation unless it displays a valid OMB control number FEE TRANSMITTAL Application Number for FY 2003 Filing Date Effective 01/01/2003. Patent fees are subject to annual revision. First Named Inventor Johnson, David A. Applicant claims small entity status. See 37 CFR 1.27 Examiner Name Art Unit TOTAL AMOUNT OF PAYMENT (S) 375 014058-010620US Attorney Docket No. METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued) 3 ADDITIONAL FEES Check ☐ Credit Card ☐ MoneyOrder ☐ Other ☐ None Deposit Accou nall Entity Large Fee Description Denosit Code (\$) Code (\$1 Paid 20-1430 Account 1051 2051 130 65 Surcharge - late filing fee or oath Number 1052 50 2052 25 Surcharge - late provisional filing fee or cover sheet Deposit 1053 130 1053 130 Non-English specification Townsend and Townsend and Crew LLP Account Name 1812 2,520 1812 2,520 For filing a request for reexamination The Commissioner is authorized to: (check all that apply) 1804 920* 1804 920* Requesting publication of SIR prior to Examiner action Charge fee(s) indicated below Credit any overpayments 1805 1,840 1805 1,840* Requesting publication of SIR after Charge any additional fee(s) during the pendency of this application Examiner action Charge fee(s) indicated below, except for the filing fee 1251 110 2251 55 Extension for reply within first month to the above-identified deposit account. 1252 2252 205 Extension for reply within second 410 FEE CALCULATION month 1253 930 2253 465 Extension for reply within third month 1. BASIC FILING FEE 1254 1.450 2254 725 Extension for raply within fourth Small Entity month Fee Description 1255 1.970 2255 985 Extension for reply within fifth month Fee Code Code (\$) (\$) Fee Paid 1401 320 2401 160 Notice of Appeal 1001 750 2001 375 Utility filing fee 375 2402 1402 320 160 Filing a brief in support of an appeal 2002 1002 330 185 Design filling fee 1403 280 2403 140 Request for oral hearing 1003 520 2003 260 Plant fifing fee Petition to institute a public use 1451 1 510 1451 1 510 2004 375 Reissue filing fee 1004 750 proceeding 1005 160 2005 Provisional filing fee 1452 2452 80 110 55 Petition to revive - unavoidable 1453 1,300 2453 650 Petition to revive - unintentional 1501 1 300 2501 650 Utility issue fee (or reissue) SUBTOTAL (4) 1502 470 2502 235 Design issue fee 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE 1503 630 2503 315 Plant issue fee 1460 130 1460 Petitions to the Commissioner 1807 50 1807 50 Petitions related to provisional applications Total Claims 14 1518 -20** = 1806 1806 Submission of Information Disclosure Claims 8021 40 8021 40 Recording each patent assignment per property (times number of Multiple Dependent properties) 1809 750 2809 375 arge Entity Ismall Entity Filing a submission after final rejection (37 CFR § 1.129(a)) For each additional invention to be 1810 750 2810 375 Fee Description (\$ (\$) examined (37 CFR § 1.129(b)) 1202 18 2202 Claims in excess of 20 Request for Continued Examination 750 1801 2801 375 1201 84 2201 Independent claims in excess of 3 42 (RCE) 1203 260 2203 140 Multiple dependent claim, if not paid Request for expedited examination 1802 900 1802 900 ** Reissue Independent claims of a design application 1204 R4 2204 42 over original patent Other fee (specify) ** Reissue claims in excess of 20 1205 and over original patent (\$) *Reduced by Basic Filing Fee Paid SUBTOTAL (3) SUBTOTAL (2) "or number previously paid, if greater, For Reissues, see above

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)

Joel St. Ackerman Registration No. (Attorney/Agent)

Signature

Date August 2), 2003

WASHING: Information or this form: Provide credit card information and authorization on PTO-2038.

This collection of Informaticy if required by 37 CFR.11-8 in 14.27. The information and authorization on PIL-2008.

This collection of Informaticy if required by 37 CFR.11-8 in 14.27. The information is required to obtain or relain a benefit by the public which is to file (and by the USPTO) to process) an application. Confideration is governed by 38 U.S.C. 122 and 27 CFR.11-4. This collection is estimated to take 12 minutes to complete function in the USPTO. The will very depending upon the individual case. Any comments on the amount of thirs you recipied to complete this form and/or suggestions for notioning this burden, should be sent to the Chief Information Officer, U.S. Patient Tackmark Office, U.S. Department of Commence, P.O. Best visto, at 450, Alexandric AV, 2237-14-10. ON MOT SEND FEES OR COMPLETED FORMS TO THIS